Elanco Animal Health (ELAN)
NYSE:ELAN
ELAN Stock Chart & Stats
$23.13
-$0.30(-2.54%)
At close: 4:00 PM EST
$23.13
-$0.30(-2.54%)
Day’s Range― - ―
52-Week Range$8.02 - $27.72
Previous CloseN/A
Volume2.53M
Average Volume (3M)5.35M
Market Cap
$11.50B
Enterprise Value$14.96B
Total Cash (Recent Filing)$545.00M
Total Debt (Recent Filing)$4.02B
Price to Earnings (P/E)―
Beta1.36
Next Earnings
May 13, 2026EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding497,168,100
10 Day Avg. Volume7,774,158
30 Day Avg. Volume5,349,429
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)1.72
Price to Sales (P/S)2.38
P/FCF Ratio39.55
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue3.17
Enterprise Value/Gross Profit6.83
Enterprise Value/Ebitda20.72
Forecast
1Y Price Target
$29.40Price Target Upside27.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)1.03
Revenue Forecast (FY)$5.00B
Bulls Say, Bears Say
Bulls Say
Financial Flexibility And Margin TrajectoryManagement's plan to reduce debt and target lower net leverage, combined with forecasted gross margin expansion and disciplined launch spending, supports potential for stronger profitability as launch costs normalize.
Product Adoption And Market ShareReported market share gains across major U.S. pet health categories, supported by stronger retail dispensing and improved clinic performance, indicate sustained adoption of recent product launches.
Regulatory OutlookManagement expects U.S. regulators to reconsider the dermatology drug label based on submitted data, which could broaden approved use and materially expand commercial potential.
Bears Say
Competition And Launch Execution RiskPotential new competitors and ongoing heavy sales and marketing investments to support launches increase execution risk and could weigh on near-term earnings if market share gains do not materialize.
Inventory-driven Margin PressureGross margins face pressure from inventory-driven inflation and the flow-through of higher inventory costs, which could weaken near-term profitability until cost savings and pricing actions take effect.
Pricing And Label ConstraintsA less favorable U.S. label and a unique U.S. pricing discount for the dermatology drug create commercial headwinds that could pressure pricing power and margins.
Elanco Animal Health News
ELAN FAQ
What was Elanco Animal Health’s price range in the past 12 months?
Elanco Animal Health lowest stock price was $8.02 and its highest was $27.72 in the past 12 months.
What is Elanco Animal Health’s market cap?
Elanco Animal Health’s market cap is $11.50B.
When is Elanco Animal Health’s upcoming earnings report date?
Elanco Animal Health’s upcoming earnings report date is May 13, 2026 which is in 44 days.
How were Elanco Animal Health’s earnings last quarter?
Elanco Animal Health released its earnings results on Feb 24, 2026. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.113 by $0.017.
Is Elanco Animal Health overvalued?
According to Wall Street analysts Elanco Animal Health’s price is currently Undervalued.
Does Elanco Animal Health pay dividends?
Elanco Animal Health does not currently pay dividends.
What is Elanco Animal Health’s EPS estimate?
Elanco Animal Health’s EPS estimate is 0.35.
How many shares outstanding does Elanco Animal Health have?
Elanco Animal Health has 497,168,100 shares outstanding.
What happened to Elanco Animal Health’s price movement after its last earnings report?
Elanco Animal Health reported an EPS of $0.13 in its last earnings report, beating expectations of $0.113. Following the earnings report the stock price went up 6.586%.
Which hedge fund is a major shareholder of Elanco Animal Health?
Currently, no hedge funds are holding shares in ELAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elanco Animal Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.40 (27.11% Upside)
$29.40 (27.11% Upside)
Blogger Sentiment
Bullish
ELAN Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 12.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
113.96%
12-Months-Change
Fundamentals
Return on Equity
-3.51%
Trailing 12-Months
Asset Growth
5.90%
Trailing 12-Months
Company Description
Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
ELAN Company Deck
ELAN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed broad positive momentum: strong product launches (Credelio Quattro, ZENRELIA), meaningful innovation revenue growth, share gains across multiple categories, improved deleveraging, and raised innovation guidance for 2026. Headwinds include higher taxes impacting EPS, lower Q4 operating cash due to one‑time tax timing, inflation and inventory cost flow‑through pressuring near‑term gross margin, and manufacturing ramp constraints for mAb launches. Management provided upbeat 2026 guidance aligned with their long‑term algorithm and emphasized productivity initiatives to support margins.View all ELAN earnings summariesELAN Stock 12 Month Forecast
Average Price Target
$29.40
▲(27.11% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Teva Pharmaceutical
―
Zoetis
―
Phibro Animal Health
―
Ownership Overview
Currently, No data available
---